LBT-3627

LBT-3627 is an experimental peptide drug derived from vasoactive intestinal peptide (VIP) intended to modulate the behavior of immune cells in cases of neurodegenerative disease such that they protect dopamine-producing cells rather than attack them. [1] The drug is currently being studied for its potential use in the treatment of Parkinson's disease.[2]

Function

LBT-3627 specifically targets the VIP2 receptor.[3] The drug may also have an effect on microglia.[1] LBT-3627 has been shown to be more stable in the body as compared to VIP.[4]

History and development

Researchers at the University of Nebraska Medical Center and Longevity Biotech, Inc. in Philadelphia first demonstrated the use of the drug in mouse models.[2][4]

A phase I trial for humans was planned for 2017,[4] but as of 2018 it was still in the preclinical development stage.[5]

References

  1. 1 2 Paddock, Catharine (December 17, 2015). "New drug that protects dopamine cells raises treatment hope for Parkinson's". Medical News Today. Retrieved December 18, 2015.
  2. 1 2 "Pioneering Neuroprotective Results Achieved in Parkinson's Disease Preclinical Studies". PR Newswire. December 16, 2015. Retrieved December 21, 2015.
  3. ↑ Azevedo, Margarida (December 21, 2015). "New Drug Candidate Shows Promise in Animal Model of Parkinson's". Parkinson's News Today. Retrieved December 21, 2015.
  4. 1 2 3 Block, Jonathan (December 17, 2015). "Drug That Protects Dopamine Cells Eyed as Parkinson's Treatment". Phychiatry Advisor. Retrieved December 21, 2015.
  5. ↑ "Research programme: peptide-based therapeutics - Longevity Biotech". AdisInsight. January 8, 2018. Highest Development Phases: Preclinical : Neurological disorders; Type 2 diabetes mellitus
This article is issued from WikiProjectMed. The text is available under Creative Commons Attribution-ShareAlike License unless otherwise noted. Additional terms may apply for the media files.